PDRN gene expression analysis reveals the molecular mechanisms by which polydeoxyribonucleotide promotes tissue regeneration, collagen synthesis, and cellular repair at the transcript level. Our comprehensive testing platform integrates RT-qPCR, RNA sequencing, and advanced bioinformatics to deliver publication-quality data for PDRN research, product development, and efficacy validation across dermatology, wound care, and regenerative medicine.
Technical Overview
Polydeoxyribonucleotide (PDRN) is a mixture of linear deoxyribonucleotide polymers with molecular weights typically ranging from 50 to 1,500 kDa, extracted primarily from salmon milt through controlled fragmentation and purification. Widely applied in regenerative medicine, dermatology, orthopedics, and aesthetic science, PDRN exerts its biological effects mainly through activation of adenosine A2A receptors, triggering intracellular cAMP-dependent signaling cascades that stimulate cell proliferation, extracellular matrix deposition, angiogenesis, and anti-inflammatory responses.
PDRN gene expression analysis quantifies the transcriptional changes induced by PDRN treatment, providing objective, mechanistic evidence of biological activity. By measuring upregulation or downregulation of target genes in fibroblasts, keratinocytes, endothelial cells, and tissue specimens, researchers can characterize dose-response relationships, define mechanisms of action, and substantiate efficacy claims for scientific publications and regulatory submissions.
- Objective quantification of PDRN bioactivity at the molecular level
- Multi-gene panel coverage spanning regeneration, inflammation, and angiogenesis pathways
- Compatibility with in vitro, ex vivo, and in vivo study designs
- Publication-ready data with rigorous controls and statistical validation
Testing Samples
Cell Samples
Cultured cells treated with PDRN at defined concentrations and time points constitute the most common sample type. Accepted cell models include primary human dermal fibroblasts, epidermal keratinocytes, human umbilical vein endothelial cells (HUVEC), preadipocytes, osteoblasts, chondrocytes, and standardized cell lines. Samples may be submitted as cell pellets, lysates in RNA stabilization reagent, or extracted total RNA with documented purity and integrity metrics.
Tissue Samples
Skin biopsies, wound bed tissue, scar tissue, and excised animal tissue can be analyzed following laser capture microdissection or whole-tissue homogenization. Tissue specimens should be snap-frozen in liquid nitrogen or preserved in RNA stabilization reagent immediately after collection to prevent RNA degradation.
Animal Model Samples
Samples derived from preclinical models, including rodent full-thickness wound healing models, UV-induced photoaging models, and tendon or bone injury models, are fully supported. We accommodate tissue sections from both PDRN-treated and vehicle-control groups, enabling robust differential expression comparisons.
PDRN Product Samples
Finished injectable solutions, lyophilized powders, and topical formulations can be submitted for biological activity characterization, allowing sponsors to verify that commercial PDRN products retain gene-modulating capacity consistent with reference standards.
Testing Items
Testing panels are structured around the principal biological activities of PDRN and can be customized to fit specific research objectives. Core gene categories include:
- Extracellular matrix and collagen synthesis: COL1A1, COL1A2, COL3A1, COL4A1, ELN, FN1, HAS2, and remodeling regulators MMP1, MMP2, MMP3, MMP9, TIMP1, TIMP2
- Inflammatory mediators: IL1B, IL6, IL8 (CXCL8), TNF, PTGS2 (COX-2), NFKB1, and related chemokines
- Growth factors and angiogenesis: VEGFA, FGF2, PDGFA, TGFB1, EGF, ANGPT1, HIF1A, KDR (VEGFR2)
- Cell proliferation and apoptosis: PCNA, MKI67, BCL2, BAX, CASP3, CDKN1A
- Antioxidant defense: SOD1, SOD2, CAT, GPX1, NQO1, HMOX1
- Adenosine receptor signaling: ADORA2A, ADORA2B and downstream cAMP pathway components
- Wound healing and barrier function: FLG, IVL, LOR, AQP3, DEFB4A
Testing Methods
All workflows begin with RNA extraction followed by rigorous quality control, including spectrophotometric purity assessment (A260/280 and A260/230 ratios), fluorometric quantification, and integrity evaluation via RIN (RNA Integrity Number) scoring. Only samples meeting predefined quality thresholds proceed to downstream analysis.
RT-qPCR
Reverse transcription quantitative PCR remains the gold standard for targeted gene expression quantification. Using validated SYBR Green or TaqMan chemistries with multiple housekeeping genes (GAPDH, ACTB, RPLP0, or 18S rRNA) selected through stability algorithms, relative expression is calculated using the ΔΔCt method with appropriate statistical testing across biological replicates.
RNA Sequencing (RNA-seq)
Whole-transcriptome sequencing on Illumina platforms enables unbiased discovery of PDRN-responsive genes and non-coding RNA species. Bioinformatics pipelines include quality trimming, reference genome alignment, differential expression analysis using DESeq2, and functional enrichment through Gene Ontology (GO) and KEGG pathway databases, generating volcano plots, heatmaps, and pathway network diagrams.
Microarray Analysis
For high-throughput screening of predefined gene sets, microarray platforms offer cost-effective profiling of thousands of targets simultaneously, suitable for large comparative studies and batch-to-batch product consistency evaluation.
Droplet Digital PCR (ddPCR)
- Absolute quantification without standard curves
- Superior sensitivity for low-abundance transcripts
- Ideal for validating RNA-seq discoveries
Applications
PDRN gene expression analysis supports a broad spectrum of research, development, and commercial objectives:
- Mechanism of action studies defining the molecular pathways underlying PDRN-driven regeneration
- In vitro efficacy substantiation for cosmetic and aesthetic product claims
- Dose optimization and treatment schedule design through systematic concentration-response and time-course experiments
- Comparative benchmarking of PDRN against other regenerative actives such as polynucleotides, hyaluronic acid, and growth factors
- Quality control verifying batch-to-batch consistency of biological activity in manufactured PDRN products
- Preclinical study support for regulatory dossiers and clinical trial justification
- Publication support with complete datasets, statistical reports, and figure-ready visualizations
FAQ
What sample quantities are required? For cell pellets, approximately 105 to 106 cells per condition are recommended. Tissue samples of 20 to 50 mg are typically sufficient, while extracted RNA submissions should contain at least 500 ng of high-quality total RNA.
Which species are supported? Assays are validated for human, mouse, rat, and other common preclinical species. Custom primer and probe design is available for non-standard organisms.
What is the typical turnaround time? RT-qPCR projects are generally completed within 10 to 15 business days after sample receipt. RNA-seq projects, including bioinformatics analysis, typically require 25 to 35 business days depending on sequencing depth and analytical complexity.
Can custom gene panels be designed? Yes. Clients may submit a target gene list for panel construction, and our technical team will design, validate, and optimize assays for the specified targets.
What controls are included? Each project incorporates no-template controls, no-reverse-transcription controls, inter-plate calibrators, and reference gene normalization. Treatment groups are compared against appropriately matched vehicle controls.
What deliverables are provided? Final reports include raw Ct values, processed expression data, fold-change calculations, statistical analysis, quality control metrics, and curated graphical outputs suitable for inclusion in manuscripts and regulatory submissions.
